Trinity Biotech

Trinity Biotech Revenue per Employee

The Revenue per Employee of Trinity Biotech (TRIB) as of Nov 10, 2026 is 75,621.76 USD. In the previous year, Revenue per Employee was 106,312.61 USD — a change of -28.87% (lower).

Revenue per Employee

75,621.76USD

YoY

-28.87%

Last updated:

Revenue per Employee of Trinity Biotech is 2025 75,621.76 USD. Revenue per Employee of Trinity Biotech was 2024 106,312.61 USD. It decreases by -28.87% lower compared to the previous year.

The Trinity Biotech Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2018
167,590.67 USD
Jan 1, 2019
156,191.71 USD
Jan 1, 2020
176,131.26 USD
Jan 1, 2021
140,153.71 USD
Jan 1, 2022
107,981.00 USD
Jan 1, 2023
98,155.44 USD
Jan 1, 2024
106,312.61 USD
Jan 1, 2025
75,621.76 USD
The Trinity Biotech Revenue per Employee history
YEARRevenue per EmployeeYoY
75,621.76USD-28.87%
106,312.61USD+8.31%
98,155.44USD-9.10%
107,981.00USD-22.96%
140,153.71USD-20.43%
176,131.26USD+12.77%
156,191.71USD-6.80%
167,590.67USD-2.12%
171,226.25USD-0.47%
172,039.72USD-0.58%
173,048.36USD-4.46%
181,124.35USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Revenue per Employee of Trinity Biotech is 75,621.76 USD in 2025.

Revenue per Employee of Trinity Biotech changed from 106,312.61 USD to 75,621.76 USD, representing a -28.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Trinity Biotech

All Key Metrics — Trinity Biotech